Core Laboratories Inc.
CLB
$10.44
-$0.16-1.51%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.32% | -4.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.32% | -4.37% | |||
| Cost of Revenue | 4.25% | -6.34% | |||
| Gross Profit | 9.71% | 4.68% | |||
| SG&A Expenses | -23.97% | 52.02% | |||
| Depreciation & Amortization | -1.26% | 1.45% | |||
| Other Operating Expenses | 81.66% | -255.20% | |||
| Total Operating Expenses | 1.40% | -2.25% | |||
| Operating Income | 63.35% | -27.63% | |||
| Income Before Tax | 593.11% | -84.28% | |||
| Income Tax Expenses | 9.45% | -57.16% | |||
| Earnings from Continuing Operations | 15,362.32% | -99.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 85.20% | -237.88% | |||
| Net Income | 7,006.49% | -102.08% | |||
| EBIT | 63.35% | -27.63% | |||
| EBITDA | 42.53% | -20.27% | |||
| EPS Basic | 7,012.12% | -102.13% | |||
| Normalized Basic EPS | 121.53% | -38.54% | |||
| EPS Diluted | 6,766.67% | -102.13% | |||
| Normalized Diluted EPS | 118.14% | -38.54% | |||
| Average Basic Shares Outstanding | -0.30% | -2.09% | |||
| Average Diluted Shares Outstanding | 1.26% | -2.09% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 1.01% | -49.07% | |||